Close Menu

The Wall Street Journal has a commentary piece from Sidney Taurel, chairman and CEO of Eli Lilly and Company, on a recent flare-up over a drug candidate in clinical trials. The heart-attack drug, prasugrel, was in two trials that were halted pending review of a few cases of adverse effects. Taurel says the media coverage that followed this not only got the story wrong, but resulted in cutting Lilly's market cap by "about $6 billion."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.